Cork Family’s Urgent Race to Save Second Son From Rare Disease
The HSE Drugs Group has deferred a decision on the public reimbursement of Skyclarys, a treatment for the degenerative condition Friedreich’s ataxia, leaving families in Ireland in an extended period of uncertainty. Following a meeting on Tuesday, the group requested further research and indicated it would review the case again in three to four weeks. … Read more